Insulin gives Denmark's Novo Nordisk a Q1 boost

(AP)—Danish pharmaceutical company Novo Nordisk A/S says first-quarter net profit rose 28 percent on strong sales of its diabetic drugs.

The world's largest insulin maker said in the first three months of 2013 was 5.9 million kroner ($1 million), up from 4.7 million kroner. Revenue for the period came in at 20 billion kroner ($3.5 billion), up 13 percent.

Chief Executive Lars Rebien Soerensen said Wednesday he was pleased by the strong insulin sales, and said the company expects to see sales grow between 9 and 11 percent this year and rising by around 10 percent.

The company's share price was up around 0.2 percent at 993 kroner in morning trading in Copenhagen.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Diabetes drugs helps boost Novo Nordisk in Q2

Aug 09, 2012

(AP) — Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 29 percent in the second quarter of 2012, chiefly spurred by strong sales of its new diabetes drugs.

Danish Novo Nordisk profit surges

Jan 31, 2013

Danish pharmaceutical company Novo Nordisk A/S on Thursday reported a 23 percent growth in fourth-quarter net profit on strong sales of diabetic drugs and gave a positive outlook as regulators worldwide begin to approve its ...

Wind turbine maker's shares tumble on profit alert

Oct 31, 2011

Shares in Danish company Vestas, the world leader in the wind turbine industry, plunged by 20 percent on Monday after the company issued a full-year profit warning over delays on several projects.

Wind turbine maker's shares plunge 19%

Jan 04, 2012

Vestas, the world leader in the wind turbine industry, saw its share price plummet around 19 percent at the opening Wednesday, a day after issuing a profit warning.

Softbank 3Q profit doubles on iPhone sales

Jan 31, 2013

Japanese phone company Softbank, owned by billionaire Masayoshi Son, says its net profit more than doubled in the October-December quarter from a year earlier, helped by strong sales of Apple's iPhone and iPads.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.